S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
NASDAQ:DCTH

Delcath Systems (DCTH) Stock Price, News & Analysis

$4.73
-0.14 (-2.87%)
(As of 04/16/2024 ET)
Today's Range
$4.66
$4.86
50-Day Range
$3.72
$5.09
52-Week Range
$2.25
$7.99
Volume
127,399 shs
Average Volume
219,493 shs
Market Capitalization
$116.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50

Delcath Systems MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
291.1% Upside
$18.50 Price Target
Short Interest
Bearish
3.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$100,001 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.45) to ($0.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.24 out of 5 stars

Medical Sector

297th out of 930 stocks

Surgical & Medical Instruments Industry

37th out of 99 stocks

DCTH stock logo

About Delcath Systems Stock (NASDAQ:DCTH)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

DCTH Stock Price History

DCTH Stock News Headlines

Start loving Mondays like this
Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!
Start loving Mondays like this
Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!
Delcath Systems Appoints Martha Rook As COO
DCTH Apr 2024 7.500 call
Delcath Announces $7 Mln Private Placement
See More Headlines
Receive DCTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
4/16/2024
Next Earnings (Estimated)
5/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:DCTH
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.50
High Stock Price Target
$21.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+290.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-47,680,000.00
Net Margins
-2,308.86%
Pretax Margin
-2,308.86%

Debt

Sales & Book Value

Annual Sales
$2.07 million
Book Value
$0.72 per share

Miscellaneous

Free Float
19,380,000
Market Cap
$116.41 million
Optionable
Optionable
Beta
0.53
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Gerard J. Michel MBAMr. Gerard J. Michel MBA (Age 61)
    MS, CEO & Director
    Comp: $671.6k
  • Dr. Johnny John M.D. (Age 59)
    Senior Vice President of Clinical Operations & Medical Affairs
    Comp: $472.16k
  • Ms. Sandra Pennell (Age 45)
    Senior VP of Finance and Principal Financial & Accounting Officer
  • Dr. Martha S. Rook Ph.D. (Age 52)
    Chief Operating Officer
  • Mr. David Hoffman
    General Counsel, Corporate Secretary & Chief Compliance Officer
  • Dr. Vojislav Vukovic M.D. (Age 57)
    Ph.D., Chief Medical Officer

DCTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Delcath Systems stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DCTH shares.
View DCTH analyst ratings
or view top-rated stocks.

What is Delcath Systems' stock price target for 2024?

4 Wall Street analysts have issued 1 year target prices for Delcath Systems' shares. Their DCTH share price targets range from $13.00 to $21.00. On average, they predict the company's share price to reach $18.50 in the next year. This suggests a possible upside of 291.1% from the stock's current price.
View analysts price targets for DCTH
or view top-rated stocks among Wall Street analysts.

How have DCTH shares performed in 2024?

Delcath Systems' stock was trading at $4.16 at the beginning of 2024. Since then, DCTH shares have increased by 13.7% and is now trading at $4.73.
View the best growth stocks for 2024 here
.

When is Delcath Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our DCTH earnings forecast
.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) announced its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.19. The firm had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative trailing twelve-month return on equity of 563.60%. During the same quarter in the prior year, the firm posted ($0.86) earnings per share.

When did Delcath Systems' stock split?

Delcath Systems's stock reverse split before market open on Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Delcath Systems?

Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DCTH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners